Washington, DC – The Association of Clinical Research Professionals (ACRP) today announces formation of a multi-stakeholder task force charged with defining the core competencies required of entry-level clinical research associates (CRAs).
The task force will identify the competencies required of entry-level CRAs (also known as monitors), develop measures of competence, and advocate for standardization of identified CRA competencies across the clinical research enterprise.
This announcement follows publication this week by ACRP of a position paper examining the current CRA workforce and calling for elimination of the commonly accepted and practiced two-year experience requirement for entry-level CRAs in favor of competence-based employment practices (see: A New Approach to Developing the CRA Workforce).
"The arbitrary 2-years' experience requirement is contributing to a shortage of CRAs in the clinical research profession and is leading to inefficiencies at contract research organization and clinical trial sponsors while doing nothing to ensure quality in clinical research," says Terri Hinkley, RN, BScN, MBA, CCRC, ACRP Interim Executive Director. "By leading this initiative ACRP plans to drive a shift in the profession that will both address the existing workforce pipeline issues and improve the quality conduct of clinical research."
As noted in ACRP's position paper, there are at least 10,000 CRA open positions in the United States alone, and there is no evidence to suggest that number will decline any time soon. A recent Brookings study, lamenting an overall employee shortage throughout the life sciences industry, singled out the CRA as one of the positions most in need of recruitment.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.